Correvio Pharma Corp.
DelistedCIK 1036141fmd_0M35QH6CV7N60V1409JM1HZT5ZManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Dec 31, 2019, 10 periods
| Line item | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 66 | 2 | 1 | 5 | 30 | 21 | 25 | 24 | 29 | 33 |
| Cost of revenue | – | – | 0 | 1 | 10 | 7 | 6 | 7 | 8 | 10 |
| Gross profit | – | – | 1 | 4 | 20 | 14 | 19 | 17 | 20 | 23 |
| Research and development | 15 | 15 | 6 | 0 | 1 | 3 | 0 | 0 | – | – |
| Selling, general and administrative | – | – | 9 | 16 | 34 | 31 | 31 | 37 | 43 | 46 |
| Total operating expenses | 29 | 28 | 27 | 20 | 37 | 36 | 33 | 40 | 47 | 50 |
| Operating income | 37 | (26) | (26) | (17) | (17) | (22) | (15) | (23) | (26) | (27) |
| Interest expense | 2 | 2 | (4) | (0) | 1 | 2 | 3 | 6 | 6 | 8 |
| Other non-operating income (expense) | (1) | (1) | 8 | 22 | (2) | (2) | (5) | (6) | 10 | (8) |
| Income before taxes | – | – | (18) | 5 | (18) | (24) | (19) | (29) | (17) | (35) |
| Income tax expense | – | – | 0 | 0 | 0 | (0) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | (18) | 5 | (18) | (24) | (20) | (30) | (17) | (35) |
| Net income | 35 | (28) | (18) | 5 | (18) | (24) | (20) | (30) | (17) | (35) |
| Net income to common shareholders | – | – | – | – | – | (24) | (20) | (30) | (17) | (35) |